Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 1
1970 1
1972 2
1973 12
1974 11
1975 15
1976 10
1977 15
1978 10
1979 5
1980 12
1981 13
1982 22
1983 20
1984 33
1985 21
1986 20
1987 21
1988 17
1989 39
1990 38
1991 46
1992 34
1993 45
1994 49
1995 57
1996 54
1997 56
1998 55
1999 66
2000 64
2001 77
2002 80
2003 72
2004 75
2005 69
2006 72
2007 82
2008 74
2009 64
2010 69
2011 87
2012 90
2013 93
2014 102
2015 120
2016 100
2017 91
2018 86
2019 97
2020 87
2021 125
2022 123
2023 101
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

2,643 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Lymphocyte-Depleted Classic Hodgkin Lymphoma"
Page 1
How I treat nodular lymphocyte-predominant Hodgkin lymphoma.
Eichenauer DA, Engert A. Eichenauer DA, et al. Blood. 2020 Dec 24;136(26):2987-2993. doi: 10.1182/blood.2019004044. Blood. 2020. PMID: 32877522 Free article. Review.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and clinical characteristics. Unlike the malignant cells in classical Hodgkin lymphoma, the disease-defining lymphocyte …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with distinct pathologic and c …
The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group.
Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L, Hoppe RT. Constine LS, et al. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1100-1118. doi: 10.1016/j.ijrobp.2018.01.011. Epub 2018 Jan 9. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722655 Free article. Review.
Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment strategies that are effective and safe. ...The complexity of treating relapsed or refractory HL derives from the spectrum of primary treatment approaches currently in use that cr …
Relapsed and refractory Hodgkin lymphoma (HL) challenges clinicians to devise treatment strategies that are effective and safe …
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, Ansell SM, Moskowitz CH, Brown L, Zhang C, Taft D, Ansari S, Sacchi M, Ho L, Herrera AF. Advani RH, et al. Blood. 2021 Aug 12;138(6):427-438. doi: 10.1182/blood.2020009178. Blood. 2021. PMID: 33827139 Free article. Clinical Trial.
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In parts 1 and 2, patients received staggered dosing of BV and Nivo in cycle …
This phase 1-2 study evaluated brentuximab vedotin (BV) combined with nivolumab (Nivo) as first salvage therapy in patients with relapsed/re …
Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z, Natkunam Y, Bair E, Tibshirani R, Warnke RA. Fan Z, et al. Am J Surg Pathol. 2003 Oct;27(10):1346-56. doi: 10.1097/00000478-200310000-00007. Am J Surg Pathol. 2003. PMID: 14508396
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow-up was obtained on 56 patients, including 26 patients who had not had recurrence of disease and 30 patients who had recurr …
Prominent sclerosis was identified in approximately 20% of cases and was frequently seen in recurrent disease. Clinical follow …
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087. Chen R, et al. J Clin Oncol. 2017 Jul 1;35(19):2125-2132. doi: 10.1200/JCO.2016.72.1316. Epub 2017 Apr 25. J Clin Oncol. 2017. PMID: 28441111 Free PMC article. Clinical Trial.
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with r …
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 …
Hodgkin's lymphoma in adults.
Townsend W, Linch D. Townsend W, et al. Lancet. 2012 Sep 1;380(9844):836-47. doi: 10.1016/S0140-6736(12)60035-X. Epub 2012 Jul 25. Lancet. 2012. PMID: 22835602 Free article. Review.
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease are excellent, and serial reductions in intensity of treatment have been made to retain the excellent prognosis while reducing the late effe …
Management of Hodgkin's lymphoma continues to develop. Outcomes for patients with favourable-risk, early-stage disease …
Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management.
Ansell SM. Ansell SM. Am J Hematol. 2016 Jun;91(4):434-42. doi: 10.1002/ajh.24272. Am J Hematol. 2016. PMID: 27001163 Free article. Review.
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually and representing approximately 11.2% of all lymphomas in the United States. DIAGNOSIS: HL is composed of two distinct disease entiti …
DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 9,050 new patients annually …
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Moskowitz CH, et al. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. Blood. 2018. PMID: 30266774 Free article. Clinical Trial.
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). . …
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodg …
Classic Hodgkin Lymphoma - Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers.
Perry AM, Smith LB, Bagg A. Perry AM, et al. Acta Med Acad. 2021 Apr;50(1):110-125. doi: 10.5644/ama2006-124.329. Acta Med Acad. 2021. PMID: 34075767 Free article. Review.
The aim of this paper is to review morphologic, immunophenotypic, and molecular features of classic Hodgkin lymphoma, as well as different prognostic markers in this neoplasm. Classic Hodgkin lymphoma (CHL) accounts for 15-25% of all lymp …
The aim of this paper is to review morphologic, immunophenotypic, and molecular features of classic Hodgkin lymphoma, a …
Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group.
Klekawka T, Balwierz W, Brozyna A, Chaber R, Dadela-Urbanek A, Koltan A, Kwasnicka J, Mitura-Lesiuk M, Muszynska-Roslan K, Przybyszewski B, Ruranska I, Smalisz K, Mizia-Malarz A, Stachowicz-Stencel T, Stolarska M, Wziatek A, Zielezinska K, Skoczen S. Klekawka T, et al. Pediatr Hematol Oncol. 2021 Oct;38(7):609-619. doi: 10.1080/08880018.2021.1894278. Epub 2021 Mar 18. Pediatr Hematol Oncol. 2021. PMID: 33734010
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare clinical entity. ...NLPHL occurred mainly in males (n = 17). Most of the patients (n = 16) had early stage disease - Stage I (n = 6) and stage II (n = 10). Four of the six patients with …
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) is a rare clinical entity. ...NLPHL occurred mainly in males (n …
2,643 results